-1.38%
9.43%
10.09%
13.92%
7.49%
56.33%
83.76%
Stock-Card

AI Spotlight on SMTI

Company Description

Sanara MedTech Inc.develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States.It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.


The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue.The company was formerly known as WNDM Medical Inc.


and changed its name to Sanara MedTech Inc.in May 2019.Sanara MedTech Inc.


was incorporated in 2001 and is based in Fort Worth, Texas.

Market Data

Last Price 36.33
Change Percentage -1.38%
Open 37.1
Previous Close 36.84
Market Cap ( Millions) 318
Volume 36254
Year High 40.75
Year Low 26
M A 50 34.98
M A 200 32.27

Financial Ratios

FCF Yield -0.63%
Dividend Yield 0.00%
ROE -19.72%
Debt / Equity 80.24%
Net Debt / EBIDTA -377.60%
Price To Book 7.78
Price Earnings Ratio -37.0
Price To FCF -159.4
Price To sales 4.07
EV / EBITDA -80.42

News

Business Breakdown

Expected Mid-Term Growth

Segment n°1 -> Soft Tissue Repair Products

Expected Growth : 8.5 %

What the company do ?

Sanara MedTech Inc.'s Soft Tissue Repair Products are bio-compatible, absorbable, and non-toxic solutions for wound closure and tissue repair.

Why we expect these perspectives ?

Sanara MedTech's Soft Tissue Repair Products segment growth of 8.5% is driven by increasing demand for minimally invasive procedures, advancements in biomaterials, and rising incidence of soft tissue injuries. Additionally, growing awareness of wound care management and expanding applications in orthopedic and sports medicine are contributing to the segment's growth.

Segment n°2 -> Bone Fusion Products

Expected Growth : 8.5 %

What the company do ?

Bone Fusion Products from Sanara MedTech Inc. are innovative, bioresorbable implants that facilitate spinal fusion, promoting bone growth and stability.

Why we expect these perspectives ?

Sanara MedTech Inc.'s Bone Fusion Products segment growth of 8.5% is driven by increasing demand for minimally invasive spine surgeries, advancements in biomaterials and nanotechnology, growing prevalence of spinal disorders, and expanding healthcare infrastructure in emerging markets.

Segment n°3 -> Royalty

Expected Growth : 8.9 %

What the company do ?

Royalty from Sanara MedTech Inc. refers to the payment made to the company for the use of its patented wound-care technology by other companies.

Why we expect these perspectives ?

Sanara MedTech Inc.'s 8.9% royalty growth is driven by increasing adoption of its wound care products, expansion into new markets, and strategic partnerships. Additionally, growing demand for advanced wound care solutions, favorable reimbursement policies, and investments in research and development are contributing to the company's growth momentum.

Sanara Medtech Inc. Products

Product Range What is it ?
Wound Cleaning Debridement A non-invasive, pain-free wound cleaning and debridement system that uses ultrasonic technology to remove dead tissue, bacteria, and other debris from wounds.
Wound Closure System A minimally invasive system that uses micro-staples to close wounds, promoting faster healing and reducing the risk of complications.
Tissue Viability Imaging A non-invasive, handheld device that uses near-infrared spectroscopy to assess tissue oxygenation and viability.
Wound Dressing with Antimicrobial Properties A range of dressings that release antimicrobial agents to prevent infection and promote a healthy wound environment.

Sanara MedTech Inc.'s Porter Forces

Sanara MedTech Inc. faces moderate threat from substitutes, as there are alternative medical devices available in the market, but they are not highly differentiated.

Sanara MedTech Inc. has a diverse customer base, which reduces the bargaining power of individual customers, giving the company an upper hand in negotiations.

Sanara MedTech Inc. relies on a few key suppliers for critical components, giving them some bargaining power, but the company's large order volumes and long-term contracts mitigate this risk.

The medical device industry is highly regulated, and new entrants face significant barriers to entry, including high R&D costs and stringent regulatory approvals, making it challenging for new companies to enter the market.

The medical device industry is highly competitive, with several established players competing for market share, leading to intense rivalry and high marketing and R&D expenses.

Strength

Weaknesses

Opportunities

Threats

Capital Structure

Value
Debt Weight 18.32%
Debt Cost 4.16%
Equity Weight 81.68%
Equity Cost 12.25%
WACC 10.77%
Leverage 22.43%

Sanara MedTech Inc. : Quality Control

Historical Valuation

Price/Earnings Ratio

Margin Valuation

Peers Valuation

Competitors

Company Rational
WRBY Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and …
RVP Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and …
ATRC AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. …
STXS Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the …
DXR Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to …

Peers Metrics

DCF BETA

Parameters

Short Term Growth
Short term Time
Long-Term Growth
WACC
Target Price
36.33$
Current Price
36.33$
Potential
-0.00%

Expected Cash-Flows

Scoring Insights

Peers Group Analysis

🥇

Daxor Logo
Daxor
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥈

Retractable Technologies Logo
Retractable Technologies
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥉

Warby Parker Logo
Warby Parker
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

4

Stereotaxis Logo
Stereotaxis
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

5

Sanara MedTech Logo
Sanara MedTech
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

6

AtriCure Logo
AtriCure
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->